Saint Louis University School of Medicine

JAMA Neurology Publishes Complete Results of Positive Phase 3 Study of REXULTI® (brexpiprazole) for Agitation Associated with Dementia Due to Alzheimer’s Disease

Retrieved on: 
Monday, November 6, 2023
Research, Mental Health, Neurology, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Behavioral neuroscience, Attention, Headache, Incidence, CMAI, Food, Mini–Mental State Examination, DSM-IV codes, Brexpiprazole, OPDC, MD, Psychiatry, Food and Drug Administration Amendments Act of 2007, Deficit spending, Verbal aggression, Dementia, Multimedia, Medicine, Interview, Pneumonia, Somnolence, Lundbeck, Locomotion, Commercialization, JAMA Neurology, Cachexia, Screaming, Caregiver, Passive-aggressive behavior, Aggression, Saint Louis University School of Medicine, MMSE, Heart, Ōtsuka, Akathisia, Contra body movement, Agitation, Medication, Tearing, Anxiety, IPA, Patient, Diagnosis, Disease, Restless, Pharmaceutical industry, Nursing, Birth control

REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease.

Key Points: 
  • REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease.
  • Participants also required a diagnosis that met The International Psychogeriatric Association’s (IPA) provisional definition of agitation in patients with cognitive impairment or dementia.
  • “Agitation associated with dementia due to Alzheimer’s disease can be very challenging and emotionally distressing for patients and family members caring for them.
  • The trial had high rates of patients completing the trial: 86.8% of the brexpiprazole group and 88.9% of the placebo group.

Kyiv to Host International Healthcare Summit on War Zone Medicine

Retrieved on: 
Tuesday, October 31, 2023
Public health, Clinical professor, Surgeon General of the United States, California Pacific Medical Center, Organization, Summit, Amputation, University of Maryland School of Public Health, Learning, Non-governmental organization, Surgeon, International healthcare accreditation, Hospital, Stanford University School of Medicine, Maryland School, University, Pain management, University of Pennsylvania Health System, Mayo Clinic, Rear admiral, Saint Louis University School of Medicine, Dentistry, Pharmaceutical industry

COLUMBUS, Ohio, Oct. 31, 2023 /PRNewswire/ -- (JANZ Corporation) -- As war rages in Ukraine and Gaza, a former U.S. Surgeon General will be among the medical professionals gathering in Kyiv next week to discuss the challenges of providing medical care in active war zones.

Key Points: 
  • Surgeon General will be among the medical professionals gathering in Kyiv next week to discuss the challenges of providing medical care in active war zones.
  • To learn more and/or register to attend physically or virtually for the International Healthcare Summit-Ukraine 2023, please visit www.internationalhealthcaresummit.org .
  • "The situation in Ukraine is absolutely catastrophic," said Dr. Andrii Strokan, chief clinical medical officer at Feofaniya Hospital in Kyiv, Ukraine.
  • Strokan, who led the team of surgeons visiting the Mayo Clinic, will be joined in Kyiv at the healthcare summit by former Surgeon General of the United States (Acting), Rear Admiral
    (ret.)

Axsome Therapeutics Presents Results of the ACCORD trial of AXS-05 in Alzheimer’s Disease Agitation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Conference

Retrieved on: 
Tuesday, October 24, 2023
Alzheimer's disease, Medical Affairs Bureau, Saint Louis University School of Medicine, Mortality, MD, Coffee, Safety, News, Professor, Conference, Doctor of Philosophy, CNS, Disease, Agitation, Poster, ADA, ACCORD, Division, Geriatric psychiatry, Therapy, NMDA, Patient, Disability, Central nervous system, Pharmaceutical industry

“Agitation is also a significant risk factor for early admission to long term care facilities.

Key Points: 
  • “Agitation is also a significant risk factor for early admission to long term care facilities.
  • The outcome of the ACCORD trial with AXS-05 demonstrating positive efficacy results in agitation associated with Alzheimer's dementia, while being generally well-tolerated, is welcome news."
  • Results of the trial demonstrated rapid and sustained clinical response in patients with ADA during the open-label AXS-05 treatment phase.
  • Details for the presentation are as follows:
    Title: Efficacy and Safety Of AXS-05 in Agitation Associated With Alzheimer’s Disease: Results From ACCORD, a Phase 3, Double-Blind, Placebo-Controlled, Relapse Prevention Trial

Twice-Yearly Lenacapavir Demonstrates Sustained Impact on Health-Related Quality of Life in People With HIV

Retrieved on: 
Tuesday, July 25, 2023
AIDS, Health, Infectious Diseases, Hospitals, Clinical Trials, Pharmaceutical, Biotechnology, HIV, Week, Hospital, Aes, OBR, Lenacapavir, Saint Louis University School of Medicine, Plasma, United Arab Emirates, MD, OB, Patient, European, United Kingdom, Infection, Safety, Pharmaceutical industry, Vaccine, Medical device, CAPELLA

In CALIBRATE, in a missing equals excluded analysis, 100% of all participants at Week 10, 20, and 30 were virologically suppressed (77/77; 58/58; 5/5, respectively).

Key Points: 
  • In CALIBRATE, in a missing equals excluded analysis, 100% of all participants at Week 10, 20, and 30 were virologically suppressed (77/77; 58/58; 5/5, respectively).
  • One CAPELLA participant who missed two non-consecutive oral lenacapavir doses did not maintain virologic suppression during OB.
  • Overall, OB demonstrated a consistent safety and tolerability profile, with treatment-emergent adverse events (AEs) similar to subcutaneous lenacapavir.
  • The use of twice-yearly lenacapavir for HIV prevention is investigational and the safety and efficacy of lenacapavir for this use have not been established.

BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related Agitation

Retrieved on: 
Thursday, June 29, 2023
Saint Louis University School of Medicine, Geriatric psychiatry, Behavioral neuroscience, Dexmedetomidine, Prevalence, ACES, Falls, Professor, PEC, Patient, Met, Psychiatry, Artificial intelligence, Therapy, Agitation, Caregiver, Disease, Medical imaging, Pharmaceutical industry

Efficacy for this dose was supported by a number of secondary measures, including CGI-I and ACES.

Key Points: 
  • Efficacy for this dose was supported by a number of secondary measures, including CGI-I and ACES.
  • The primary endpoint was not met for the 40 mcg dose, with a 5.7 point reduction from baseline in PEC score.
  • “Today, there are approximately 100 million Alzheimer’s-related agitation episodes in the U.S. annually, and there are no episodic treatment options for these patients.
  • We believe that our data from TRANQUILITY II show that BXCL501 has the potential to treat acute episodes of agitation in patients with mild to moderate Alzheimer’s disease, if approved.

Lazurite® Names Physicians to Medical Advisory Board

Retrieved on: 
Thursday, February 16, 2023
Science, Research, Pharmaceutical, Medical Supplies, Surgery, Health, Medical Devices, Clinical Trials, Shoulder, Cleveland, American Sports Medicine Institute, Elective surgery, Cleveland Guardians, New York University Grossman School of Medicine, NYU Langone Health, Staten Island University Hospital, Safety, Arthroscopy, General surgery, Sports medicine, American Orthopaedic Society for Sports Medicine, Long Island University, Elbow, Food, Sport, MT, Movement, Cleveland Clinic, Saint Louis University School of Medicine, American Board of Commissioners for Foreign Missions, American Academy, Orthopedic surgery, Arthroscopy Association of North America, Knee, NYU, Multimedia, Regulation of tobacco by the U.S. Food and Drug Administration, Icahn School of Medicine at Mount Sinai, Surgeon, DRS, Dentistry, Schickendantz, Lazurite, Medicine

have joined the company’s medical advisory board.

Key Points: 
  • have joined the company’s medical advisory board.
  • He completed his residency in orthopedic surgery at NYU Medical Center and held a fellowship in Sports Medicine at American Sports Medicine Institute in Alabama.
  • He is a member of a number of professional and medical societies, including the American Board of Orthopedic Surgery, the Arthroscopy Association of North America, and the American Orthopaedic Society for Sports Medicine.
  • He is a member of a number of professional and medical societies, including the American Board of Orthopedic Surgery, a fellow with the American Academy of Orthopedic Surgeons and the Major League Baseball Team Physicians Association, among many others.

AMERICAN SKIN ASSOCIATION ANNOUNCES RENEWAL OF SPOTS EDUCATION OUTREACH GRANT - (SPOTS)

Retrieved on: 
Tuesday, February 14, 2023
DRS, Dermatology, PSA, Skin cancer, Council, Capitol Region Education Council, Acceleration, Pamphlet, Melanoma, Patient, Education, Incidence, Skin, Chowdhury, Risk, Parent, ASA, Student, Saint Louis University School of Medicine, Knowledge, Curriculum, Heart, SPOTS, Partnership, Growth, Adolescence, Saint Louis University, Washington University in St. Louis, Nursing

NEW YORK, Feb. 14, 2023 /PRNewswire/ -- American Skin Association (ASA) announced the renewal of its support for the SPOTS (Sun Protection Outreach Teaching by Students) program.

Key Points: 
  • NEW YORK, Feb. 14, 2023 /PRNewswire/ -- American Skin Association (ASA) announced the renewal of its support for the SPOTS (Sun Protection Outreach Teaching by Students) program.
  • SPOTS is a community outreach program designed to teach students from preschool through high school about the importance of early detection and prevention of skin cancer.
  • The impact of skin cancer education, using the SPOTS educational pamphlet, for patients with skin of color was evaluated.
  • Increasing awareness of behaviors and education of the consequences of sun exposure is at the heart of the mission of the American Skin Association," adds Humberto C. Antunes, Co-Chair of the ASA's Education Council.

Promaxo Announces Appointment of Dr. Prithipal S. Sethi as Chief Medical Officer of Urology

Retrieved on: 
Tuesday, December 20, 2022
Cell and molecular biology, Saint Louis University School of Medicine, MRI, Health, CMO, University of California, Berkeley, Center of excellence, Golden, Patient, AI, American Board of Commissioners for Foreign Missions, University, Medical college, Medical College of Wisconsin, Robotics, Bachelor of Science, Molecular biology, Medical device, Medicine, Urology

OAKLAND, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, today announced the appointment of Dr. Prithipal S. Sethi as Chief Medical Officer (CMO) of Urology.

Key Points: 
  • OAKLAND, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Promaxo, Inc. (“Promaxo” or the “Company”), a medical imaging, robotics, and AI technology company, today announced the appointment of Dr. Prithipal S. Sethi as Chief Medical Officer (CMO) of Urology.
  • Dr. Sethi is a board-certified urologist who has been practicing urology for more than 25 years.
  • “We are excited to have Dr. Sethi join us as our Chief Medical Officer of Urology.
  • Sethi has the clinical experience, proven leadership ability, and key relationships to make a meaningful impact at Promaxo.

Pardes Biosciences Appoints Laurie Smaldone Alsup, M.D. and John C. Pottage, Jr., M.D. to Board of Directors

Retrieved on: 
Wednesday, September 14, 2022
Autoimmunity, Lists of diseases, American Board of Internal Medicine, PRDS, Fordham University, GSK, Industry, Patient, Saint Louis University School of Medicine, Colgate University, Nasdaq, ViiV Healthcare, American Board of Commissioners for Foreign Missions, COVID-19, Yale school, Vertex Pharmaceuticals, Yale School of Medicine, Annual report, Medical specialty, SEC, Infection, Strategic management, Severe acute respiratory syndrome coronavirus 2, Intention, Senior, Forward-looking statement, Board of directors, Board, GLOBE, Therapy, Faculty, Department, HIV, Private Securities Litigation Reform Act, Drug development, Pardes, Internal medicine, Pfizer, Bristol Myers Squibb, Rush Medical College, Medicine, Pharmaceutical industry, Biology

Dr. Smaldone Alsup has over 30 years of biopharmaceutical industry experience, specializing in commercially successful product approvals and global regulatory strategy.

Key Points: 
  • Dr. Smaldone Alsup has over 30 years of biopharmaceutical industry experience, specializing in commercially successful product approvals and global regulatory strategy.
  • She currently serves as the Chief Medical Officer and Chief Scientific Officer of NDA Group AB, a regulatory and drug product development consulting company.
  • Prior to joining NDA Group AB, she served as the President and Chief Scientific Officer of PharmApprove LLC, a regulatory communications consultancy.
  • He is board certified in both Internal Medicine and Infectious Disease by the American Board of Internal Medicine.

Florida's First Smart Knee Implant Procedure for Total Knee Replacement Performed by Daniel A. Jones, MD, of South Florida Orthopaedics & Sports Medicine

Retrieved on: 
Wednesday, July 13, 2022
Technology, Treasure Coast, Personalization, Graduate medical education, Record, De novo, Hip, Patient, Adult, MD, GLOBE, Saint Louis University School of Medicine, Gait, Preferred walking speed, Motion, Mayo Clinic School of Health Sciences, Failure, Pain, Persona, Dentistry, Tradition

STUART, Fla., July 13, 2022 (GLOBE NEWSWIRE) -- South Florida Orthopaedics & Sports Medicine surgeon Daniel A. Jones, MD, officially implanted the world's first smart knee implant in the state of Florida on May 26, 2022.

Key Points: 
  • STUART, Fla., July 13, 2022 (GLOBE NEWSWIRE) -- South Florida Orthopaedics & Sports Medicine surgeon Daniel A. Jones, MD, officially implanted the world's first smart knee implant in the state of Florida on May 26, 2022.
  • The implant, known as the Persona IQ, is the world's first and only smart knee implant granted De Novo status by the U.S. Food & Drug Administration for total knee replacement surgery.
  • Daniel A. Jones, MD, is an orthopaedic surgeon with fellowship training in adult reconstructive hip and knee replacement surgery.
  • For media inquiries, please contact South Florida Orthopaedics & Sports Medicine at southflaortho.com/contact , [email protected], or (772) 288-2400.